M. Toguchi

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

Matthew D. Seftel, John Kuruvilla, Tom Kouroukis et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 47 citations

Neurotrophic effect of Semaphorin 4D in PC12 cells

Shiho Fujioka, Kenta Masuda, M. Toguchi et al. · Biochemical and Biophysical Research Communications · 2003 · 33 citations

Semaphorin 4D, Neuroprotection, Neuroscience +4

Members of the CIP4 family of proteins participate in the regulation of platelet‐derived growth factor receptor‐β‐dependent actin reorganization and migration

M. Toguchi, Ninna Richnau, Aino Ruusala et al. · Biology of the Cell · 2009 · 32 citations · Full text

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

Britta Vormoor, Gareth J. Veal, Martin J. Griffin et al. · Pediatric Blood & Cancer · 2016 · 32 citations · Full text

Studies on cytotoxic effect of nickel ions on three cultured fibroblasts

Masayuki Taira, M. Toguchi, Yoshinori Hamada et al. · Journal of Materials Science Materials in Medicine · 2001 · 27 citations